Skip To Main Content
Helena W. Rodbard on Muck Rack

Helena W. Rodbard

As seen in: Wiley, Wiley Online Library, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, Healio, Endocrine Today, Diabetes Care Magazine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Helena W.

Contact Helena W., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Error in Table

|
By Julio Rosenstock, Juan P Frías, Helena W. Rodbard, Santiago Tofé
| JAMA: Journal of the American Medical Association Verified
Error in Table The Original Investigation titled “Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial,”1 published online October 3, 2023, was corrected to fix an error in Table 3 in which a row was erroneously labeled as adverse events leading to "study treatment discontinuation," rather than "study discontinuation." This article was corrected online.
Open in Who Shared Issue with article?

Practical strategies to manage obesity in type 2 diabetes

|
By Helena W. Rodbard, Katharine D. Barnard-Kelly, Oliver Schnell, Carina Mauersberger
| Wiley Online Library Verified
CONFLICT OF INTEREST STATEMENT HWR served as a consultant for and/or has received research support from Bayer, Boehringer Ingelheim, Eli Lilly, Inversago, Medtronic, Merck, MSD, Novo Nordisk, Pacira and Sanofi. KBK is a founder and shareholder at Spotlight-AQ Ltd. She has received research support from Dexcom, JDRF, Embecta, Novo Nordisk and Roche Diabetes Care. She has also received honoraria from Sanofi.
Open in Who Shared Issue with article?

Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials

|
By Hiren Patel, Kamlesh Khunti, Helena W. Rodbard
| Wiley Online Library Verified
1 INTRODUCTION Globally, 60% of people with type 2 diabetes (T2D) have obesity (defined as a body mass index ≥30 kg/m2).1 People with T2D and obesity are at a higher risk of developing cardiometabolic complications compared with people with T2D alone.2 Thus, current guidelines recommend weight management as one of the priorities in the treatment of T2D as part of a multifactorial approach.3 Incretin-based therapies such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) and...
Open in Who Shared Issue with article?
See all 12 articles